Patents by Inventor Mari Nakano

Mari Nakano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR DETERMINING SIDE EFFECTS OF TRASTUZUMAB AND KIT FOR SAME
    Publication number: 20220154259
    Abstract: A side effect of trastuzumab is predicted by using a gene polymorphism associated with the side effect of trastuzumab. The genotype of a gene polymorphism specified by one selected from the group consisting of rs9316695, rs11932853, rs28415722, rs7406710 and rs8032978 is determined and a side effect from administration of trastuzumab is determined based on the genotype determined.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 19, 2022
    Applicants: Tokyo Kohan Co., Ltd, Japanese Foundation For Center Research
    Inventors: Hitoshi Zembutsu, Chihiro Unagawa, Mari Nakano
  • Pharmaceutical composition
    Patent number: 6818662
    Abstract: The present invention provides a pharmaceutical composition comprising N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and sulfobutyl ether &bgr;-cyclodextrin or a salt thereof, wherein sulfobutyl ether &bgr;-cyclodextrin increases the solubility of N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and improves the photostability.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: November 16, 2004
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Shusei Ito, Akio Miwa, Mari Nakano
  • Pharmaceutical composition
    Publication number: 20030225032
    Abstract: The present invention provides a pharmaceutical composition comprising N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and sulfobutyl ether &bgr;-cyclodextrin or a salt thereof, wherein sulfobutyl ether &bgr;-cyclodextrin increases the solubility of N-(3-chloro-4-morpholin-4-yl)phenyl-N′-hydroxyimidoformamidine and improves the photostability.
    Type: Application
    Filed: August 14, 2002
    Publication date: December 4, 2003
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Shusei Ito, Akio Miwa, Mari Nakano
  • Preparation for nasal administration
    Patent number: 6617353
    Abstract: A preparation for nasal administration which comprises as an effective ingredient a prostaglandin derivative represented by Formula (I): wherein X is a halogen atom, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s) or a C4-13 cycloalkylalkyl group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 0 to 3, and n is an integer of 1 to 4 or a pharmaceutically acceptable salt thereof and a water-soluble polymer.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: September 9, 2003
    Assignee: Taisho Pharmaceutical Co., Ltd.
    Inventors: Shusei Ito, Kenji Yamada, Ayumi Koda, Mari Nakano